Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor John Geddes has been appointed to the WA Handley Professorship of Psychiatry and will take up this post in November 2021. He will be a fellow of Merton College. A donation from the WA Handley Trust endowed the first Chair of Psychiatry in the University of Oxford’s Department of Psychiatry, which was founded in 1969.

John Geddes
It’s a true honour to be appointed to a statutory chair at Oxford University. Even in normal times Oxford is an astonishing place and I am simply awestruck by what this place has done in the battle against the virus. The WA Handley Chair will help me ensure that we learn from this to bring the same urgency, widespread collaboration and intellectual inspiration to bear on mental health. - Professor John Geddes, Head of Department of Psychiatry

The Department of Psychiatry and Merton College, one of the oldest colleges in Oxford with a strong commitment to excellence in research and teaching, held a rigorous search and selection process for this prestigious clinical academic post. The position provides an unparalleled opportunity to develop and sustain a large scale research programme, supported by the world-leading clinical research infrastructure in Oxford.

Mental health research is a priority for the University of Oxford, which is working closely with Oxford Health NHS Foundation Trust through the NIHR Oxford Health Biomedical Research Centre.

Previous post holders include the late Professor Michael Gelder, the founder of the Department of Psychiatry at the University of Oxford, and Professor Guy Goodwin.

Read the full story on the Department of Psychiatry website

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.